Skip to main content
Caplight Logo









Flashpoint Therapeutics

Flashpoint Therapeutics

Private
Evanston, IllinoisHealthcare & Life Scienceshttps://www.flashpoint.bio/

Last Round

Seed

Oct 25, 2023

Est. Valuation

$35M

Total Funding Raised

$20M

Company Overview

Flashpoint Therapeutics is a biotechnology company that develops precision-engineered structural nanomedicines for cancer and other diseases by co-delivering RNA, DNA, and peptide cargo to specific cells.

Sector

Healthcare & Life Sciences

Verticals

Biotechnology, Drug Discovery, Precision Medicine

Business Model

B2B

Customer Profile

Services & Consulting

AI Layer

Non-AI

Keywords

nanoparticle deliverynucleic acid therapeuticsSNAdrug delivery techspherical nucleic acidnanomedicinedrug delivery platformgenetic medicinetargeted therapybiotech R&Ddrug discoveryCRISPR deliverymRNA deliverybiotech licensing

Historical Pricing

Historical view of private secondary pricing and transaction trends.

Unlock Pricing Charts

Sign up to view complete historical pricing and secondary transactions.

Caplight Momentum Score

Proprietary index based on bid/ask volume and sentiment.

View Momentum History

Track how buyer interest and sentiment changes over time.

Flashpoint Therapeutics Comparables

Compare Flashpoint Therapeutics with similar companies based on industry and business-model similarity.

Flashpoint Therapeutics comparables — related companies by embedding similarity
CompanySimilarityMarket Cap
DNA Nanobots
86%
SNC Therapeutics, Inc.
86%
Entos Pharmaceuticals
85%

Flashpoint Therapeutics Funding Rounds

Historical fundraising activity

Data table
RoundDateAmount RaisedValuationInvestorsSources
SeedOct 25, 2023
SeedOct 25, 2023
Pre SeedJan 30, 2023

Key People

Founding team and executive leadership

Barry Labinger

Chief Executive Officer

Executive Team

Flashpoint Therapeutics Investors

Notable investors and investment history

Flashpoint Therapeutics investors
InvestorRounds
Beta LabSeed

Market signals

Structured signals derived from secondary market and firmographic data.

  • Jul 28, 2025

    Barry Labinger appointed as new Chief Executive Officer.

Flashpoint Therapeutics Filings

Explore SEC and related filing metadata, where available.

Flashpoint Therapeutics filings preview — column headings only; records require access
TypeDateAmount OfferedAmount SoldFilingPagesDownload

Filing documents are not displayed on this public page. Request access to learn about available coverage.

Request access

Frequently Asked Questions

Common questions about Flashpoint Therapeutics's valuation, stock price, and market status.

Is Flashpoint Therapeutics a public or private company?

Flashpoint Therapeutics is a private company.

What is the current stock price of Flashpoint Therapeutics?

Flashpoint Therapeutics is a private company with no public stock price. No recent secondary market data is available.

How much is Flashpoint Therapeutics worth (valuation)?

Flashpoint Therapeutics's valuation is estimated at $35.0M based on funding round data.

Can I buy Flashpoint Therapeutics stock?

Flashpoint Therapeutics shares may be available on secondary markets subject to transfer restrictions. Caplight facilitates secondary market transactions for accredited investors. Visit https://www.caplight.com to learn more.

When was Flashpoint Therapeutics's last funding round?

Flashpoint Therapeutics's most recent funding round was Seed on October 25, 2023.

Who are the main investors in Flashpoint Therapeutics?

Key investors in Flashpoint Therapeutics include Beta Lab.

Will Flashpoint Therapeutics IPO soon?

No public IPO plans have been announced for Flashpoint Therapeutics.

How can I track Flashpoint Therapeutics secondary market activity?

Caplight tracks bids, offers, and trades for private companies. Visit https://www.caplight.com to monitor Flashpoint Therapeutics's secondary market activity and sign up for updates.

Firmographic Details

HeadquartersEvanston, Illinois
Employee Range14
Year Founded2022
Last FundingOct 25, 2023

Institutional Data Access

Join leading institutional investors using Caplight to access private market data, discover pricing, and execute secondary block trades.

Requires verified institutional or accredited status.

See something wrong or outdated?